Drug Combination Details
| General Information of the Combination (ID: C58031) | |||||
|---|---|---|---|---|---|
| Name | Citral NP Info | + | Pirarubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| In-vivo Model | For the colorectal peritoneal carcinomatosis (CRPC) experiments, mouse-derived colorectal cancer cells CT26 (5 * 106 cells in 0.5 mL of serum-free medium) were intraperitoneal inoculated into the flanks of Balb/C mice. | |||||
| Experimental
Result(s) |
Combination treatment of citral potentiates the efficacy of hyperthermic intraperitoneal chemoperfusion with pirarubicin for colorectal cancer. | |||||
